Artelo Biosciences, Inc.

In the quarter to June 2026, EPS grew 94.7% and free cash flow fell 879.2%, each against the same quarter a year earlier.

2.70 0.04 −1.46%

Follow ARTL

Alert me

	Older periods	Sep '25	Dec '25	Mar '26	Jun '26
ROE Full definition →	+8 more TTM periods Free account	(436.14%)	(1,625.11%)	(367.70%)	(705.71%)
ROA Full definition →		(219.08%)	(343.49%)	(167.97%)	(234.30%)
ROIC Full definition →		0.00%	0.00%	0.00%	(865.85%)
Return on Tangible Assets Full definition →		411.84%	384.56%	(293.16%)	(434.53%)
Average Days of Receivables Full definition →		—	—	—	—
Free Cash Flow per Share Full definition →		(280.96)	(223.62)	(98.83)	(41.93)
Free Cash Flow Full definition →		(8.18)	(8.52)	(8.11)	(12.63)
Other line items
Cash ROIC Full definition →		(752.16%)	1,267.86%	(47.88%)	(137.39%)
Accounts Payable Turnover Full definition →		0.00	0.00	0.00	0.00
Average Days of Payables Full definition →		0.00	0.00	0.00	0.00
Tax Rate Full definition →		0.00	0.00	0.00	0.00
Research and Development Expense of Revenue Full definition →		0.00%	0.00%	0.00%	0.00%
Selling, General and Administrative Expense of Revenue Full definition →		0.00%	0.00%	0.00%	0.00%
Share Based Compensation of Revenue Full definition →		0.00%	0.00%	0.00%	0.00%
Interest Coverage Full definition →		(65.77)	(40.44)	(29.21)	(33.04)
Operating CF/Net income Full definition →		0.65	0.66	0.60	1.00
Depreciation/Fixed assets Full definition →		0.00	0.00	0.00	0.00
Capex/Depreciation Full definition →		0.00	0.00	0.00	0.00
Revenue per Share Full definition →		0.00	0.00	0.00	0.00
Operating CF per Share Full definition →		(280.96)	(223.62)	(98.83)	(41.93)
Capex per Share Full definition →		0.00	0.00	0.00	0.00

Columns are period end dates · fundamentals updated 28 Sep 2026